Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers

Molecular Cancer Therapeutics

Volumn 7, Issue 1, 2008, Pages 10-18

  Stevens, Ellen V ^a   Nishizuka, Satoshi ^a   Antony, Smitha ^a   Reimers, Mark ^a   Varma, Sudhir ^a   Young, Lynn ^b   Munson, Peter J ^b   Weinstein, John N ^a   Kohn, Elise C ^a   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CARMUSTINE; CISPLATIN; HYDROXYUREA; LOMUSTINE; MITOZOLOMIDE; PACLITAXEL; PROTEIN HYDROLYSATE; TENIPOSIDE; TIOGUANINE; TRABECTEDIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL TYPE; COLON CANCER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SENSITIVITY; EXCISION REPAIR; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; XERODERMA PIGMENTOSUM;

CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; COLONIC NEOPLASMS; DIOXOLES; DNA REPAIR; FEMALE; GENE EXPRESSION PROFILING; HUMANS; OVARIAN NEOPLASMS; PROTEIN ARRAY ANALYSIS; TETRAHYDROISOQUINOLINES; TUMOR MARKERS, BIOLOGICAL;

EID: 38349186343     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0192     Document Type: Article

References (42)

1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7:573-84.
2. McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol 1998;25:340-8.
3. Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 2005;11:6100-2.
4. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002;62:4899-902.
5. Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 2003;39:112-9.
6. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-74.
7. Takebayashi Y, Nakayama K, Kanzaki A, et al. Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon and lung carcinomas: implication for their roles of carcinogenesis in human solid tumors. Cancer Lett 2001;174:115-25.
8. Koberle B, Masters JR, Hartley JA, Wood RD. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999;9:273-6.
9. Verweij J. Ecteinascidin-743 (ET-743): early test or effective treatment in soft tissue sarcomas? J Clin Oncol 2005;23:5420-3.
10. Fayette J, Coquard IR, Alberti L, et al. ET-743: a novel agent with activity in soft-tissue sarcomas. Curr Opin Oncol 2006;18:347-53.
11. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996;35:13303-9.
12. Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 1999;42:2493-7.
13. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7:961-6.
14. Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001;37:97-105.
15. Nishizuka S, Charboneau L, Young L, et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 2003;100:14229-34.
16. Shankavaram UT, Reinhold WC, Nishizuka S, et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 2007;6:820-32.
17. Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays which capture disease progression show activation of prosurvival pathways at the cancer invasion front. Oncogene 2001;20:1981-9.
18. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-23.
19. Weinstein JN. Spotlight on molecular profiling: "integromic" analysis ofthe NCI-60 cancer cell lines. Mol Cancer Ther 2006;5:2601-5.
20. Weinstein JN, Myers TG, O'Connor PM, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997;275:343-9.
21. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-44.
22. Rochette PJ, Bastien N, McKay BC, Therrien JP, Drobetsky EA, Drouin R. Human cells bearing homozygous mutations in the DNA mismatch repair genes hMLH1 or hMSH2 are fully proficient in transcription-coupled nucleotide excision repair. Oncogene 2002;21:5743-52.
23. Umar A, Koi M, Risinger JI, et al. Correction of hypermutability, N-methyl-N′-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res 1997;57:3949-55.
24. Oshima RG, Baribault H, Caulin C. Oncogenic regulation and function of keratins 8 and 18. Cancer Metastasis Rev 1996;15:445-71.
25. McCluggage WG, Wilkinson N. Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology 2005;47:231-47.
26. Washio F, Ueda M, Ito A, Ichihashi M. Higher susceptibility to apoptosis following ultraviolet B irradiation of xeroderma pigmentosum fibroblasts is accompanied by upregulation of p53 and downregulation of bcl-2. Br J Dermatol 1999;140:1031-7.
27. D'Incalci M, Jimeno J. Preclinical and clinical results with the natural marine product ET-743. Expert Opin Investig Drugs 2003;12:1843-53.
28. Grasselli G, Malossi A, Colombo N, et a. Phase I and pharmacokinetic (PK) study ofectein ascidin-743 (ET, trabectedin) and cisplatin (P) combination in pre-treated patients (pts) with selected advanced solid tumors. Proc Am Soc Clin Oncol 2003;22:542.
29. Parma G, Bauer J, Noberasco C, et al. Yondelis TM (Et-743, trabectedin) antitumor activity in ovarian cancer patients prestreated with platinum-taxane regimens. Ann Oncol 2003;14:iii52.
30. Sabbatini P. New agents and new formulations for the treatment of ovarian cancer. Clin Adv Hematol Oncol 2005;3:840-2.
31. Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005;23:1867-74.
32. Ganesan AK, Hunt J, Hanawalt PC. Expression and nucleotide excision repair of a UV-irradiated reporter gene in unirradiated human cells. Mutat Res 1999;433:117-26.
33. Welsh C, Day R, McGurk C, Masters JR, Wood RD, Koberle B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 2004;110:352-61.
34. Koberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR, Masters JR. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer 1997;70:551-5.
35. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol 2000;60:1305-13.
36. Yu JJ, Mu C, Dabholkar M, Guo Y, Bostick-Bruton F, Reed E. Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell lines. Int J Mol Med 1998;1:617-20.
37. Britten RA, Liu D, Tessier A, Hutchison MJ, Murray D. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 2000;89:453-7.
38. Stevens EV, Posadas EM, Davidson B, Kohn EC. Proteomics in cancer. Ann Oncol 2004;15 Suppl 4:iv167-71.
39. Stevens EV, Liotta LA, Kohn EC. Proteomic analysis for early detection of ovarian cancer: a realistic approach? Int J Gynecol Cancer 2003;13 Suppl 2:133-9.
40. Marchini S, Marrazzo E, Bonomi R, et al. Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743. Eur J Cancer 2005;41:323-33.
41. Nishizuka S, Chen ST, Gwadry FG, et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res 2003;63:5243-50.
42. Paull KD, Shoemaker RH, Hodes L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development ofmean graph and COMPARE algorithm. J Natl Cancer Inst 1989;81:1088-92.